Home>>Signaling Pathways>> Tyrosine Kinase>> ALK>>SMAD3 Inhibitor, SIS3

SMAD3 Inhibitor, SIS3

Catalog No.GC44903

SMAD3 Inhibitor, SIS3 is a potent and selective inhibitor of Smad3 phosphorylation.

Products are for research use only. Not for human use. We do not sell to patients.

SMAD3 Inhibitor, SIS3 Chemical Structure

Cas No.: 1009104-85-1

Size Price Stock Qty
500μg
$83.00
In stock
1mg
$150.00
In stock
5mg
$454.00
In stock

Tel:(909) 407-4943 Email: sales@glpbio.com

Customer Reviews

Based on customer reviews.

  • GlpBio Citations

    GlpBio Citations
  • Bioactive Compounds Premium Provider

    Bioactive Compounds Premium Provider

Sample solution is provided at 25 µL, 10mM.

Description Chemical Properties Product Documents Related Products

SMAD3 is a receptor-regulated intracellular protein that functions downstream of TGF-β and activin receptors and mediates their signaling, playing a role in cell proliferation, differentiation, apoptosis and formation of extracellular matrix. SMAD3 Inhibitor, SIS3 selectively inhibits TGF-β and activin signaling by suppressing Smad3 phosphorylation (IC50 = 3 µM) without affecting the MAPK/p38, ERK, or PI3-kinase signaling pathways.[1] It has been shown to reduce TGF-β1-induced type 1 procollagen expression and myofibroblast differentiation in normal dermal fibroblasts as well as scleroderma fibroblasts.[1]

Reference:
[1]. Jinnin, M., Ihn, H., and Tamaki, K. Characterization of SIS3, a novel specific inhibitor of Smad3, and its effect on transforming growth factor-β1-induced extracellular matrix expression. Molecular Pharmacology 69(2), 597-607 (2006).

Reviews

Review for SMAD3 Inhibitor, SIS3

Average Rating: 5 ★★★★★ (Based on Reviews and 14 reference(s) in Google Scholar.)

5 Star
100%
4 Star
0%
3 Star
0%
2 Star
0%
1 Star
0%
Review for SMAD3 Inhibitor, SIS3

GLPBIO products are for RESEARCH USE ONLY. Please make sure your review or question is research based.

Required fields are marked with *

You may receive emails regarding this submission. Any emails will include the ability to opt-out of future communications.